Sep 29, 2020 / 01:00PM GMT
Operator
Ladies and gentlemen, welcome to the MorphoSys and Incyte Joint Conference Call. (Operator Instruction] The conference is being recorded. (Operator Instructions)
I would like to turn the conference over to Dr. Anja Pomrehn, please go ahead, madam.
Anja Pomrehn - MorphoSys AG - SVP
Thank you. Ladies and gentlemen, good afternoon, or good morning. My name is Anja Pomrehn, Head of Investor Relations at MorphoSys. It is my pleasure to welcome you to this joint MorphoSys and Incyte conference call and webcast to discuss the unmet need and global opportunities for tafasitamab in non-Hodgkin lymphomas.
We have the great pleasure to have Professor Gilles Salles opening our call today with a presentation on r/r DLBCL and the frontline DLBCL landscape, followed by speakers from both Incyte and Morphosys. From Morphosys, we have Jean-Paul Kress, CEO; Malte Peters, Chief Research and Development Officer; and Roland Wandeler, Chief Operating Officer. Speakers from Incyte will be General Manager North America, Barry Flannelly; and Steven Stein, Incyte's CMO
MorphoSys AG and Incyte Corp to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas Investor Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot